Jiangxi Provincial Drug Administration announcement: 15 varieties of 18 batches of sampling failed

Pharma Network January 8th, 2021 - On January 6th, 2021, jiangxi Provincial Drug Administration issued the first issue of Jiangxi Province 2021 drug supervision and sampling information announcement.
15 varieties and 18 batches did not meet the standards.
non-conforming Chinese herbs and drink tablets (8 batches): bamboo, masturbation, small grass, Qin , flat shellfish, red flowers (2 batches), big grass.
Non-conforming solid preparations (10 batches): vitamin C calcium capsules, psychic capsules (2 batches), zinc sulfate tablets, cold and hot particles, compound dansin tablets, compound wearing heart lotus tablets (2 batches), octa-Jinyi mother pills, aspirin intestinal solution tablets do not meet the requirements of the items: characteristics, examination, content determination.
the Small Editor noted that five batches were 2020 production lot numbers, meaning that the five batches would be punished under the new Drug Administration Act.
In order to strengthen drug quality supervision and ensure the safety of public drug use, according to the Drug Administration Law and related laws and regulations and the drug sampling plan of Jiangxi Province, drug regulatory departments and inspection agencies at all levels in our province have carried out supervision and sampling of drug production, operation and use units throughout the province.
The current issue of drug sampling information is reported as follows: First, the announcement: after verification and confirmation, the current period of supervision and sampling information published as follows: 15 varieties of 18 batches do not meet the standard provisions (see annex), non-compliance items including characteristics, inspection, content determination and so on.
2. The Jiangxi Provincial Drug Administration has tasked the relevant departments to take the necessary control measures such as seizure, seizure, suspension of sales and recall of non-compliant drugs, and to investigate and punish the production enterprises and the sampling units in accordance with relevant laws and regulations.
Annex: Summary of Information On Drug Supervision and Sampling Non-Compliance (No. 1 of 2021).xlsx January 6, 2021 (Public Attributes: Active Disclosure) Source: Jiangxi Provincial Drug Administration